---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-25-000033"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:21:37.328563+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maravai restates Q2/Q3 2024 financials due to $3.9M revenue recognition error; Q4 revenue down 24%

## Summary
- Non-reliance on Q2 and Q3 2024 financials; restatement corrects $3.9M revenue timing error.
- Q4 revenue $56.6M (-23.7% YoY); Adjusted EBITDA loss of $1.1M vs +$20.5M a year ago.
- Full year 2024 revenue $259.2M (-10.3% YoY); net loss $259.6M includes $166M goodwill impairment.
- Voluntarily prepaid $228M of Term Loan with cash; year-end cash $322M.
- Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman.

## SEC filing metadata
- accession: 0001823239-25-000033
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/0001823239-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/mrvi-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-25-000033
- JSON: https://secwatch.observer/filing/0001823239-25-000033.json
- Plain text: https://secwatch.observer/filing/0001823239-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.